BiotechTube

E2020 + E2020

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer's Type Dementia

Conditions

Alzheimer's Type Dementia

Trial Timeline

Mar 1, 2012 → Mar 1, 2015

NCT ID
NCT01539031

About E2020 + E2020

E2020 + E2020 is a phase 3 stage product being developed by Eisai for Alzheimer's Type Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT01539031. Target conditions include Alzheimer's Type Dementia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01539031Phase 3Completed
NCT01276353Phase 2Completed

Competing Products

20 competing products in Alzheimer's Type Dementia

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
85
FK962Astellas PharmaPhase 2
52
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85